ライフサイエンスコーパス: vancomycin-resistant Enterococcus

1 hicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus.

2 sistant Staphylococcus aureus infections and vancomycin-resistant enterococcus.

3 ction was masked by the prior isolation of a vancomycin-resistant enterococcus.

4 osa, 15 of 86 (17.4%; 95% CI 9.4% to 25.4%), vancomycin-resistant Enterococcus, 25 of 180 (13.9%, 95%

5 to appropriate antibiotic for patients with vancomycin-resistant Enterococcus (4.2 versus 43.7 h; P=

6 For vancomycin-resistant Enterococcus, a four-variable class

7 thicillin-resistant Staphylococcus aureus or vancomycin-resistant Enterococcus admission surveillance

8 hicillin-resistant Staphylococcus aureus and vancomycin-resistant enterococcus are inconsistent with

9 nterococcal domination increased the risk of Vancomycin-resistant Enterococcus bacteremia 9-fold, and

10 For patients with vancomycin-resistant Enterococcus bacteremia, the mean t

11 Vancomycin-resistant Enterococcus bloodstream infections

12 Vancomycin-resistant Enterococcus bloodstream infections

13 ancomycin on susceptibility to C. difficile, vancomycin-resistant Enterococcus, carbapenem-resistant

14 proof of concept, wild-type (ATCC 29212) and vancomycin-resistant Enterococcus cells were incubated a

15 methicillin-resistant Staphylococcus aureus, vancomycin-resistant enterococcus, Clostridium difficile

16 There were no cases of vancomycin-resistant Enterococcus colonization in patien

17 e detected, including increased incidence of vancomycin-resistant Enterococcus colonization or diseas

18 hicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus colonization were intr

19 cility in the past year were associated with vancomycin-resistant Enterococcus colonization.

20 relatedness, including the first known U.S. vancomycin-resistant enterococcus (E. faecalis strain V5

21 ses consisted of 1 patient with recalcitrant vancomycin-resistant Enterococcus faecalis (VRE) and 2 p

22 against vancomycin-susceptible organisms and vancomycin-resistant Enterococcus faecalis (VRE) of VanB

23 . aureus (MRSA), Streptococcus pyogenes, and vancomycin-resistant Enterococcus faecalis (VRE).

24 eus (MSSA, MRSA, and TRSA, respectively) and vancomycin-resistant Enterococcus faecalis (VRE).

25 sistant Streptococcus pneumoniae (PRSP), and vancomycin-resistant Enterococcus faecalis (VRE).

26 Vancomycin-resistant Enterococcus faecalis (VREfs) is an

27 Vancomycin-resistant Enterococcus faecalis (VREfs) is an

28 A chromogenic medium for identification of vancomycin-resistant Enterococcus faecalis and Enterococ

29 investigate the changes to PG composition in vancomycin-resistant Enterococcus faecalis following the

30 n of the cell envelope of a clinical pair of vancomycin-resistant Enterococcus faecalis isolates from

31 and January 1995, we identified a cluster of vancomycin-resistant Enterococcus faecalis isolates invo

32 We found that GML suppresses growth of vancomycin-resistant Enterococcus faecalis on plates wit

33 rains carry transposon Tn1546, acquired from vancomycin-resistant Enterococcus faecalis, which is kno

34 hicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus faecalis.

35 hicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus faecalis.

36 rst clinical isolate of linezolid-resistant, vancomycin-resistant Enterococcus faecium (LRVRE).

37 stant S. aureus (1.3 +/- 0.4 microg/mL), and vancomycin-resistant Enterococcus faecium (MIC(50) 2.9 +

38 tbreaks involving three important pathogens: vancomycin-resistant Enterococcus faecium (n=19), methic

39 sus group (1), Streptococcus pneumoniae (6), vancomycin-resistant Enterococcus faecium (VRE FCM) (16)

40 onization of the gastrointestinal tract with vancomycin-resistant Enterococcus faecium (VRE) has beco

41 A mouse model of vancomycin-resistant Enterococcus faecium (VRE) intestin

42 Genomic DNA extracted from 45 vancomycin-resistant Enterococcus faecium (VRE) isolates

43 REA), and epidemiological data for typing 45 vancomycin-resistant Enterococcus faecium (VRE) isolates

44 Thirty-two isolates of vancomycin-resistant Enterococcus faecium (VRE) recovere

45 llin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus faecium (VRE), and bet

46 llin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus faecium (VRE), Escheri

47 To investigate the dissemination of vancomycin-resistant Enterococcus faecium (VREF) in a 72

48 Vancomycin-resistant Enterococcus faecium (VREF) was iso

49 n-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus faecium (VREF) with MI

50 n-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus faecium (VREF).

51 Vancomycin-resistant Enterococcus faecium (VREfm) is a l

52 Vancomycin-resistant Enterococcus faecium (VREfm) is an

53 mia, 54 (19.6%) were due to rESKAPE strains (vancomycin-resistant Enterococcus faecium [0], methicill

54 medium designed to recover and differentiate vancomycin-resistant Enterococcus faecium and Enterococc

55 Gram-positive bacteria (high priority) were vancomycin-resistant Enterococcus faecium and meticillin

56 rointestinal colonization by ampicillin- and vancomycin-resistant Enterococcus faecium C68 in a mouse

57 lishment of gastrointestinal colonization by vancomycin-resistant Enterococcus faecium C68 in a mouse

58 OG1RF and against two serologically related, vancomycin-resistant Enterococcus faecium clinical isola

59 The patient remained febrile and grew vancomycin-resistant Enterococcus faecium from the cereb

60 In particular, vancomycin-resistant Enterococcus faecium infections hav

61 ons; lower respiratory tract infections; and vancomycin-resistant Enterococcus faecium infections, in

62 ted States in late 1999 for the treatment of vancomycin-resistant Enterococcus faecium infections.

63 an also identify isolated colonies as either vancomycin-resistant Enterococcus faecium or Enterococcu

64 dition, this serum killed two (28%) of seven vancomycin-resistant Enterococcus faecium strains.

65 methicillin-resistant Staphylococcus aureus, vancomycin-resistant Enterococcus faecium, and beta-lact

66 fied that both inhibited and dispersed MRSA, vancomycin-resistant Enterococcus faecium, and Staphyloc

67 e may find future use as antibiotics against vancomycin-resistant Enterococcus faecium, methicillin-r

68 hicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus faecium.

69 S), we identified one neonate colonized with vancomycin-resistant Enterococcus faecium.

70 hicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus faecium.

71 reus, vancomycin-intermediate S. aureus, and vancomycin-resistant Enterococcus faecium.

72 ately controlled and powered, infection with vancomycin-resistant enterococcus has had more of an eff

73 hicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus in a neurocritical car

74 k we analyzed data observed on the spread of vancomycin-resistant Enterococcus in an intensive care u

75 hicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus in neurocritical care

76 46 has only been described in human clinical vancomycin-resistant enterococcus isolates unique to the

77 ifficile infection and dense colonization by vancomycin-resistant Enterococcus, K. pneumoniae, and E.

78 pears to be a safe and effective therapy for vancomycin-resistant enterococcus meningitis.

79 im-sulfamethoxazole-resistant MRSA (n = 10), vancomycin-resistant Enterococcus (n = 37), high-level g

80 ria monocytogenes, Bacillus anthracis, and a vancomycin-resistant Enterococcus sp. with MIC or IC50 v

81 d for detection of Staphylococcus aureus and vancomycin-resistant Enterococcus species (VRE) using a

82 istance to colonization by clinically vexing vancomycin-resistant Enterococcus species.

83 ation of methicillin resistant S. aureus and vancomycin resistant Enterococcus spp. was completed an

84 y detecting and discriminating genotypes for vancomycin-resistant Enterococcus spp. in the clinical l

85 icillin-resistant Staphylococcus aureus, and vancomycin-resistant Enterococcus spp. in the environmen

86 ncept, amplification of a gene specific to a vancomycin-resistant Enterococcus strain was performed o

87 hicillin-resistant Staphylococcus aureus and vancomycin-resistant Enterococcus surveillance cultures.

88 Indeed, a delayed vancomycin-resistant Enterococcus transmission component

89 n-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE) among ICU patien

90 by the highly antibiotic-resistant bacterium vancomycin-resistant Enterococcus (VRE) can exceed 10(9)

91 lin azide agar plus vancomycin to screen for vancomycin-resistant enterococcus (VRE) colonization.

92 Vancomycin-resistant Enterococcus (VRE) has become a sig

93 n-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococcus (VRE) have achieved si

94 -resistant Staphylococcus aureus (MRSA), and vancomycin-resistant Enterococcus (VRE) in patients with

95 Nosocomial vancomycin-resistant Enterococcus (VRE) infections have

96 Treatment of vancomycin-resistant Enterococcus (VRE) infections is li

97 Bloodstream infection (BSI) to due vancomycin-resistant Enterococcus (VRE) is an important

98 n-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE) is driving the d

99 Infections attributable to vancomycin-resistant Enterococcus (VRE) strains have bec

100 ecovered from perirectal swabs collected for vancomycin-resistant Enterococcus (VRE) surveillance as

101 llin-resistant Staphylococcus aureus (MRSA), vancomycin-resistant Enterococcus (VRE), and MDR Enterob

102 erior to direct plating for the detection of vancomycin-resistant enterococcus (VRE), but vancomycin

103 with antibiotic-resistant bacteria, such as vancomycin-resistant Enterococcus (VRE), is a dangerous

104 ighly antibiotic-resistant bacteria, such as vancomycin-resistant Enterococcus (VRE), is a growing cl

105 nce can result in intestinal domination with vancomycin-resistant Enterococcus (VRE), leading to bloo

106 n-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant Enterococcus (VRE), while also exhi

107 n-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococcus (VRE).

108 sistant S. aureus (MRSA), S. pneumoniae, and vancomycin-resistant Enterococcus (VRE).

109 n-resistant Staphylococcus aureus (MRSA) and vancomycin-resistant enterococcus (VRE).

110 al of 142 stool specimens were evaluated for vancomycin-resistant enterococcus (VRE).

111 An adolescent with vancomycin-resistant Enterococcus was given standard dos

112 thicillin-resistant Staphylococcus aureus or vancomycin-resistant Enterococcus) was constructed.